These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1917516)

  • 1. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates.
    Harrison A; Walker CA; Parker D; Jankowski KJ; Cox JP; Craig AS; Sansom JM; Beeley NR; Boyce RA; Chaplin L
    Int J Rad Appl Instrum B; 1991; 18(5):469-76. PubMed ID: 1917516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
    Williams LE; Lewis MR; Bebb GG; Clarke KG; Odom-Maryon TL; Shively JE; Raubitschek AA
    Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.
    Camera L; Kinuya S; Garmestani K; Wu C; Brechbiel MW; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH
    J Nucl Med; 1994 May; 35(5):882-9. PubMed ID: 8176477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3.
    Mohsin H; Fitzsimmons J; Shelton T; Hoffman TJ; Cutler CS; Lewis MR; Athey PS; Gulyas G; Kiefer GE; Frank RK; Simon J; Lever SZ; Jurisson SS
    Nucl Med Biol; 2007 Jul; 34(5):493-502. PubMed ID: 17591549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
    Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
    Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution in tumour-bearing mice of two 90Y-labelled biotins using three-step tumour targeting.
    Chinol M; Paganelli G; Sudati F; Meares C; Fazio F
    Nucl Med Commun; 1997 Feb; 18(2):176-82. PubMed ID: 9076775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
    Goodwin DA; Meares CF; Watanabe N; McTigue M; Chaovapong W; Ransone CM; Renn O; Greiner DP; Kukis DL; Kronenberger SI
    Cancer Res; 1994 Nov; 54(22):5937-46. PubMed ID: 7954426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 90Y.B72.3 against pancreatic cancer: dosimetric and biological analysis.
    Mehta MP; Kubsad SS; Fowler JF; Verma AK; Hsieh JT; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 1990 Sep; 19(3):627-31. PubMed ID: 2211210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
    Lewis MR; Raubitschek A; Shively JE
    Bioconjug Chem; 1994; 5(6):565-76. PubMed ID: 7873659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).
    DeNardo GL; Kroger LA; DeNardo SJ; Miers LA; Salako Q; Kukis DL; Fand I; Shen S; Renn O; Meares CF
    Cancer; 1994 Feb; 73(3 Suppl):1012-22. PubMed ID: 8306243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 90Y-DTPA and 90Y-DOTA for potential application in intra-vascular radionuclide therapy.
    Pandey U; Mukherjee A; Sarma HD; Das T; Pillai MR; Venkatesh M
    Appl Radiat Isot; 2002 Sep; 57(3):313-8. PubMed ID: 12201136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method.
    Li M; Meares CF; Zhong GR; Miers L; Xiong CY; DeNardo SJ
    Bioconjug Chem; 1994; 5(2):101-4. PubMed ID: 8031871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative biodistributions of indium-111-labelled macrocycle chimeric B72.3 antibody conjugates in tumour-bearing mice.
    Turner A; King DJ; Farnsworth AP; Rhind SK; Pedley RB; Boden J; Boden R; Millican TA; Millar K; Boyce B
    Br J Cancer; 1994 Jul; 70(1):35-41. PubMed ID: 8018538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
    DeNardo SJ; Zhong GR; Salako Q; Li M; DeNardo GL; Meares CF
    J Nucl Med; 1995 May; 36(5):829-36. PubMed ID: 7738660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of intravenously administered 111In- and 90Y-labeled B72.3 immunoconjugate (GYK-DTPA) in beagle dogs.
    Quadri SM; Shao Y; Blum JE; Leichner PK; Williams JR; Vriesendorp HM
    Nucl Med Biol; 1993 Jul; 20(5):559-70. PubMed ID: 8358341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA).
    Camera L; Kinuya S; Garmestani K; Brechbiel MW; Wu C; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH
    Eur J Nucl Med; 1994 Jul; 21(7):640-6. PubMed ID: 7957350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
    Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.